MANE Stock: Price, Earnings History and SEC Filings
Veradermics, Incorporated (MANE) last traded at $139.69, down 2.89% on the latest session and up 15.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.58 against an analyst estimate of $-0.58, a beat of 0.0%.
$139.69 -2.89%
1 month+15.23%
52-week high$146.58
52-week low$32.00
Volume464,764
ExchangeNYSE
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MANE earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-0.58 | $-0.58 | +0.00% |
| Mar 2026 | May 12, 2026 | $-1.32 | $-0.56 | -135.71% |
MANE beat the analyst EPS estimate in 0 of its last 2 reported quarters. Source: Nasdaq.
Latest SEC filings for MANE
SEC filing data is not available right now. You can search for MANE on SEC EDGAR.
MANE news
- Why This Hair Restoration Biotech's Shares Are SoaringOct 25, 2026 · fool.com
- Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major BreakthroughOct 22, 2026 · finance.yahoo.com
- Veradermics’ stock up on male hair loss trial successOct 19, 2026 · clinicaltrialsarena.com
- Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” TreatmentOct 19, 2026 · tikr.com
- Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth ResultsOct 19, 2026 · marketbeat.com
- Veradermics stock surges as hair loss drug meets Phase 3 goalsOct 19, 2026 · finance.yahoo.com
- Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness studyOct 19, 2026 · biopharmadive.com
- Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair LossOct 19, 2026 · finance.yahoo.com
About Veradermics, Incorporated
Veradermics, Incorporated (MANE) is a US-listed public company on NYSE.